• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research

Prevalence and Incidence of Cardiovascular and Renal Diseases in Type 1 Compared with Type 2 Diabetes: A Nationwide French Observational Study of Hospitalized Patients
CONCLUSIONS: Although the crude prevalent burden of CV diseases may be lower in T1DM than in T2DM, patients with T1DM may have a higher risk of incident MI, HF, all-cause death and CV death above 60 years of age, highlighting the need for improved prevention in this population.PMID:36736892 | DOI:10.1016/j.diabet.2023.101429
Source: Diabetes and Metabolism - February 3, 2023 Category: Endocrinology Authors: Pierre Henri Ducluzeau Gr égoire Fauchier Julien Herbert Carl Semaan Jean Michel Halimi Denis Angoulvant Laurent Fauchier Source Type: research

Type 2 diabetes and cardiorenal syndromes. A nationwide French hospital cohort study
CONCLUSION: . Patients with T2DM represent almost half of patients with CRS and are younger than their non-diabetic counterparts. T2DM doubles the risk of CRS and increases the risk of death, cardiovascular outcome, and end-stage kidney disease but not ischemic stroke after CRS.PMID:36931430 | DOI:10.1016/j.diabet.2023.101441
Source: Diabetes and Metabolism - March 17, 2023 Category: Endocrinology Authors: Valentin Maisons Jean-Michel Halimi Gr égoire Fauchier Jean-Baptiste de Fr éminville Nicolas Goin Juliette Gueguen Philippe Gatault B énédicte Sautenet Denis Angoulvant Julien Herbert Arnaud Bisson Pierre-Henri Ducluzeau Laurent Fauchier Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19